ESMO Conference Coverage
Featured Articles
(Forbes) Oct 3, 2019 - New trial suggests that doctor's shouldn't wait to add targeted therapy drugs to standard breast cancer treatment. Results from a clinical trial show that adding ribociclib, a targeted therapy drug, to the standard treatment plan for women with advanced hormone-receptor positive/HER2- breast cancer helps...
Read Article
(Northwestern Medicine) Sept 30, 2019 - Genetic-based treatment nearly doubles time without disease progression in metastatic prostate cancer. For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially...
Read Article
Latest Articles
October 10, 2019
October 08, 2019
October 03, 2019
October 01, 2019
October 01, 2019
October 01, 2019
October 01, 2019
October 01, 2019
View More
News Commentary
Editor Image
01 Oct, 2019 | by H. Jack West, MD
The impact of the CheckMate-227 trial remains to be seen. While it was positive...
View Comment
Editor Image
01 Oct, 2019 | by H. Jack West, MD
An important result that should satisfy the holdouts who were waiting on a...
View Comment
View More
OBR Blog
By: Stephanie Hawthorne, Ph.D., Senior Director, Clinical & Scientific Assessment, Kantar Health and Tari Awipi,... Read more
September 28, 2015
By: Stephanie Hawthorne, Ph.D., Senior Director, Clinical & Scientific Assessment, Kantar Health and Len Kusdra,... Read more
September 28, 2015

OBR Tweets

Apr 08
H. Jack West, MD: We have yet to see the results of the CheckMate-9LA trial, upon which this application is based,… https://t.co/QZIUuFK0ZP

Apr 03
Howard S. Hochster, MD: Interesting news on the KEYNOTE-177 first line MSI-H colon cancer trial. This is a 1:1 ran… https://t.co/Nx3Qp46jxN

Apr 01
Dean Gesme, MD: The reported low false positive rate in this large validation data set and high diagnostic acumen f… https://t.co/rGmVtpQ5lu

Mar 31
William McGivney, PhD: Kudos to CIGNA and to Humana and all those who helped drive the decisions of these two large… https://t.co/HF8BZCWGF7

Mar 30
H. Jack West, MD: This provides another option that is pretty much a lateral move compared to atezolizumab with che… https://t.co/hnkRD0AfXw

Mar 26
Howard S. Hochster, MD: There is no question that SARS-CoV-2 will prove to be a major challenge to all health care… https://t.co/EyJijktM68

Mar 25
OBR speaks to providers at community oncology practices like Florida Cancer Specialists & Research Institute (FCS)… https://t.co/3qyne3w9gE

Mar 25
Dr. David Penson of Vanderbilt University Medical Center @VUmedicine delves into Financial toxicity and its negativ… https://t.co/o2IUnKvcff

Mar 25
Dr. Azra Raza @AzraRazaMD, an Oncologist at @Columbia, speaks to us about her recently published book @thefirstcell… https://t.co/x1HmTvHta7

Mar 25
H. Jack West, MD: An excellent piece that highlights what the history of cancer research should be teaching the wor… https://t.co/QAEpZJP8ov